Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Belite Bio, Inc
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
November 13, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
November 07, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
November 06, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
October 27, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
August 08, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
August 04, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
July 27, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
July 24, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
May 10, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
May 10, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
May 04, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
April 25, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
April 11, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
March 31, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
March 31, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
November 18, 2022
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
October 20, 2022
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
October 01, 2022
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.